I am a Professor of Medical Oncology at University College London (UCL) and a Consultant Medical Oncologist at UCL Hospitals (UCLH), with a specialist interest in treating lung cancer. I graduated from St Mary’s Hospital Medical School, University of London in 1982, undertook postgraduate internal medicine training at the London teaching hospitals of St Mary’s, St Bartholomew’s and King’s College Hospitals before completing specialist oncology CRC fellowship training at Guy’s Hospital, London and Christie Hospital, Manchester. During this time, I was awarded the American Association for Cancer Research (AACR) UpJohn Award in 1993, McElwain Prize by The Association of Cancer Physician (ACP) for outstanding cancer research in 1994 and a PhD degree by University of Manchester in 1994. I was appointed a Consultant Medical Oncologist at UCLH in 1998 and a Professor of Medical Oncology at UCL in 2010.
As an internationally acknowledged leading lung cancer specialist, I have led several UK-based lung cancer research trials over the past 2 decades, which have changed clinical practice and improved treatment outcomes. My group established gemcitabine/carboplatin chemotherapy regimen to treat lung cancer, initiated thalidomide trials as a potential lung cancer weapon, examined the smart drug erlotinib to treat poor performance lung cancer and patients with multiple brain metastases and more recently demonstrated platinum is superior to non-platinum drugs to treat lung cancer. My research trials have been recognised at major international conferences with many invited Presidential, Plenary and Oral Lectures at World Lung Cancer Conference, ASCO and ESMO.
I am Clinical Lead of the Thoracic Medical Oncology Unit at UCLH, Clinical co-Lead of the Cancer Research UK Lung Cancer Centre of Excellence and Chair of the London Lung Cancer Group. I was previously a chairperson for the National Cancer Research Institute (NCRI) Lung Cancer Advanced Disease Subgroup, NCRI Brain New-agents Clinical Subgroup and previous committee member of CTACC, NCRI Lung, NCRI Brain and NCRI Lymphoma Groups. I sat on several national and international executive cancer committees, is a grant reviewer for several cancer research organisations, manuscripts peer reviewer for many research journals, member of a number of international cancer societies & advisor to NIHR HTA, NIHR HSRIC, NICE & MHRA on new cancer drugs. I have published over 150 peer-reviewed papers, abstracts and book chapters, many as first or senior author in high impact journals including Cancer Research, JCO, JNCI, Lancet Oncology, Lancet, Nature, NEJM & Science.